Cited by 770Immune cells in cancerCancer Immunotherapy and BiomarkersChemokine receptors and signaling

The DOI matches its Crossref record; 49 of the 50 references it cites were found in a registry or an index.

Disruption of CXCR2-Mediated MDSC Tumor Trafficking Enhances Anti-PD1 Efficacy

Open access

Highfill, Steven L., Cui, Yongzhi, Giles, Amber J., Smith, Jillian P., Zhang, Hua, Morse, Elizabeth, Kaplan, Rosandra N., Mackall, Crystal L.·2014·Science Translational Medicine

DOI 10.1126/scitranslmed.3007974PMC PMC6980372

Open this paper in CoChat — free account

Abstract

Preventing trafficking of myeloid-derived suppressor cells to the tumor site enhances the efficiency of checkpoint blockade.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Integrity signals

Registry

Crossref · 10.1126/scitranslmed.3007974

Cites

49 of 49 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Improved Survival with Ipilimumab in Patients with Metastatic Melanoma
Hodi, F. S., O'Day, S. J., McDermott, D. F., Weber, R. W., Sosman, J. A., Haanen, J. B., Gonzalez, R., Robert, C., Schadendorf, D., Hassel, J. C., et al. (2010) · New England Journal of Medicine · doi:10.1056/nejmoa1003466 · Cited by 15,155
The blockade of immune checkpoints in cancer immunotherapy
Pardoll, D. M. (2012) · Nature Reviews Cancer · doi:10.1038/nrc3239 · Cited by 13,838
Safety, activity, and immune correlates of anti–PD-1 antibody in cancer
Topalian, S. L., Hodi, F. S., Brahmer, J. R., Gettinger, S. N., Smith, D. C., McDermott, D. F., Powderly, J. D., Carvajal, R. D., Sosman, J. A., Atkins, M. B., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1200690 · Cited by 12,628
Safety and activity of anti-PD-L1 antibody in patients with advanced cancer
Brahmer, J. R., Tykodi, S. S., Chow, L. Q. M., Hwu, W.-J., Topalian, S. L., Hwu, P., Drake, C. G., Camacho, L. H., Kauh, J., Odunsi, K., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1200694 · Cited by 7,945
Engagement of the Pd-1 Immunoinhibitory Receptor by a Novel B7 Family Member Leads to Negative Regulation of Lymphocyte Activation
Freeman, G. J., Long, A. J., Iwai, Y., Bourque, K., Chernova, T., Nishimura, H., Fitz, L. J., Malenkovich, N., Okazaki, T., Byrne, M. C., et al. (2000) · The Journal of Experimental Medicine · doi:10.1084/jem.192.7.1027 · Cited by 5,294 · cited 1×
“Signaling of PD1 on T cells via PD-L1 (B7-H1) or PD-L2 (B7-DC) inhibits T cell receptor–mediated activation by recruitment of the SHP2 phosphatase (2).”
Background
Tumor-associated B7-H1 promotes T-cell apoptosis: A potential mechanism of immune evasion
Dong, H., Strome, S. E., Salomao, D. R., Tamura, H., Hirano, F., Flies, D. B., Roche, P. C., Lu, J., Zhu, G., Tamada, K., et al. (2002) · Nature Medicine · doi:10.1038/nm730 · Cited by 5,025
Ipilimumab plus Dacarbazine for Previously Untreated Metastatic Melanoma
Robert, C., Thomas, L., Bondarenko, I., O'Day, S., Weber, J., Garbe, C., Lebbe, C., Baurain, J.-F., Testori, A., Grob, J.-J., et al. (2011) · New England Journal of Medicine · doi:10.1056/nejmoa1104621 · Cited by 4,496
Nivolumab plus Ipilimumab in Advanced Melanoma
Wolchok, J. D., Kluger, H., Callahan, M. K., Postow, M. A., Rizvi, N. A., Lesokhin, A. M., Segal, N. H., Ariyan, C. E., Gordon, R.-A., Reed, K., et al. (2013) · New England Journal of Medicine · doi:10.1056/nejmoa1302369 · Cited by 4,230 · cited 1×
“Combination regimens appear to be even more potent with response rates of 53% in metastatic melanoma (22).”
Background
Coordinated regulation of myeloid cells by tumours
Gabrilovich, D. I., Ostrand-Rosenberg, S., & Bronte, V. (2012) · Nature Reviews Immunology · doi:10.1038/nri3175 · Cited by 3,544 · cited 2×
“These results are consistent with previous reports demonstrating that GrMDSCs at the tumor site are highly dependent on migration from the BM or spleen and undergo minimal proliferation within the tumor bed (13).”
BackgroundResult
Involvement of PD-L1 on tumor cells in the escape from host immune system and tumor immunotherapy by PD-L1 blockade
Iwai, Y., Ishida, M., Tanaka, Y., Okazaki, T., Honjo, T., & Minato, N. (2002) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.192461099 · Cited by 3,261

Show all 50 references

Sorted by citations

Items 601–700 of 770

Potential Mechanisms for Immunotherapy Resistance in Adult Soft-Tissue Sarcoma
Kret, Z. S., Sweder, R. J., Pollock, R. E., & Tinoco, G. (2025) · Targeted Oncology · doi:10.1007/s11523-025-01145-5 · Cited by 7
“Inhibition of CXCR with small-molecule inhibitors has shown promise in improving outcomes in STS and enhancing the activity of programmed cell death protein 1 (PD-1) inhibitors [44, 45].”
Response Challenges to Cancer Immunotherapies
Al-Janabi, I. I. (2022) · Al-Rafidain Journal of Medical Sciences · doi:10.54133/ajms.v2i.65 · Cited by 5
Nanoparticle accumulation in liver may induce resistance to immune checkpoint blockade therapy
Dai, H., Yang, Q., Sun, R., Zhang, Y., Ma, Q., Shen, Y., Wang, B., Chen, Y., Xu, J., Tian, B., et al. (2022) · Nano Research · doi:10.1007/s12274-022-5142-4 · Cited by 5
Tissue contexture determines the pattern and density of tumor-infiltrating immune cells in HPV-associated squamous cell carcinomas of oropharynx and uterine cervix
Pavelková, L., Táborská, E., Syding, L. A., Plačková, K., Simonova, E., Hladíková, K., Hensler, M., Laco, J., Koucký, V., Zábrodský, M., et al. (2024) · Translational Oncology · doi:10.1016/j.tranon.2024.101884 · Cited by 6
“As CXCL1 was shown to be associated with CXCR2 + MDSC migration [29,31,32], our data suggest that tumor cells of cervical origin directly attract MDSCs into the TME.”
Background
Novel CXCR2 antibodies exhibit enhanced anti-tumor activity in pancreatic cancer
Rahimizadeh, P., Kim, S., Yoon, B. J., Jeong, Y. S., Lim, S., Jeon, H., Lim, H. J., Park, S. H., Park, S., Kong, D.-H., et al. (2025) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2025.117966 · Cited by 5
Armed Hunter Killers: Discerning the Role of Adoptive T-Cell Transfer for Glioblastoma
Samaha, H., El‐Naggar, S., & Ahmed, N. M. (2015) · Immunotherapy · doi:10.2217/imt.15.22 · Cited by 5
MMTV-NeuT/ATTAC mice: a new model for studying the stromal tumor microenvironment
Yuan, H., Wang, X., Jin, L., Zhang, Q., Brandina, I., Alexandrov, I. M., & Glazer, R. I. (2018) · Oncotarget · doi:10.18632/oncotarget.24233 · Cited by 5
“This outcome suggests that therapy targeting, in part, chemokine receptor pathways including Cxcl1/Cxcr2, may be an effective approach for reducing or preventing the tumor-promoting effect of the inflammatory TME [25, 26].”
Background
Mutational and immunologic Landscape in malignant Salivary Gland Tumors harbor the potential for novel therapeutic strategies
Witte, H. M., Gebauer, N., & Steinestel, K. (2022) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2022.103592 · Cited by 5
Emerging hallmark of gliomas microenvironment in evading immunity: a basic concept
Arifianto, M. R., Meizikri, R., Haq, I. B. I., Susilo, R. I., Wahyuhadi, J., Hermanto, Y., & Faried, A. (2023) · The Egyptian Journal of Neurology Psychiatry and Neurosurgery · doi:10.1186/s41983-023-00635-5 · Cited by 6
“CXCL8 expression by GBM has been shown to regulate the entry of MDSCs into the tumor environment via the CXCR2 receptor [125].”
Background
The Role of Myeloid Derived Suppressor Cells in Urothelial Carcinoma Immunotherapy
Puttmann, K. T., Duggan, M. C., Mortazavi, A., Diaz, D. A., Carson, W. E., & Sundi, D. (2019) · Bladder Cancer · doi:10.3233/blc-190219 · Cited by 5
“MDSC targeting approaches in these studies have included histamine [61] TGF inhibition, [62] phenformin (an anti-diabetic biguanide) [63] CXCR2 inhibition, [64] sorafenib, [41] all-trans-retinoic-acid (ATRA), [65] ibrutinib (an inhibitor of the Bruton’s tyrosine kinase pathway in MDSC), [66] inhibition of”
Method
Promising Chimeric Antigen Receptors for Non-B-Cell Hematological Malignancies, Pediatric Solid Tumors, and Carcinomas
Appelbaum, J., Pinto, N. R., & Orentas, R. J. (2019) · Elsevier eBooks · doi:10.1016/b978-0-323-66181-2.00011-1 · Cited by 5
Machine learning–based insights into circulating autoantibody dynamics and treatment outcomes in patients with NSCLC receiving immune checkpoint inhibitors
Wei, F., Takeda, H., Azuma, K., Nakahara, Y., Igarashi, Y., Murotani, K., Saito, H., Murakami, S., Kondo, T., Kouro, T., et al. (2025) · Frontiers in Immunology · doi:10.3389/fimmu.2025.1666030 · Cited by 5
CXCL5 neutralization mitigates cancer cachexia by disrupting CAF-cancer cell crosstalk
Kim, H., Kim, S.-W., Kim, J.-H., Lee, S. H., Joo, K.-H., Lee, S., Lee, H., Min, J., Cho, S., Jung, D., et al. (2025) · Journal of Biomedical Science · doi:10.1186/s12929-025-01192-0 · Cited by 4
“CXCL5 has also been studied as a therapeutic target for the prevention of tumor angiogenesis or as an enhancer of cancer drug efficacy [74, 75].”
Integrative Immune Signature of Complementary Circulating and Tumoral Biomarkers Maximizes the Predictive Power of Adjuvant Immunotherapeutic Benefits in High-risk Melanoma
Tarhini, A. A., Obermayer, A., Lee, S. J., LaFramboise, W. A., Hodi, F. S., Karunamurthy, A. D., Eljilany, I., Chen, D., Hwu, P., Naqa, I. E., et al. (2025) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-24-3980 · Cited by 4
Prostate Cancer Immunotherapy: Time to Move Beyond Checkpoint Inhibitors
Abel, M. L., Warner, A., Karzai, F. H., & Madan, R. A. (2025) · ImmunoTargets and Therapy · doi:10.2147/itt.s549873 · Cited by 4
“79 As with IL-8, CXCR2 binding can allow MDSCs to promote tumor growth.”
Immunomodulatory effect of splenectomy in lung cancer mouse xenograft models receiving radiation therapy
Kim, Y., Choi, C., Park, J. H., Ahn, W.-G., Shin, S.-W., Kim, S., & Noh, J. M. (2022) · Radiation Oncology Journal · doi:10.3857/roj.2021.00885 · Cited by 4
Targeted immune activation in pediatric solid tumors: opportunities to complement local control approaches
Vonderhaar, E. P., Dwinell, M. B., & Craig, B. T. (2023) · Frontiers in Immunology · doi:10.3389/fimmu.2023.1202169 · Cited by 4
“In an interesting study that tested timing of checkpoint therapy administration, targeting PD-1 is only effective when given very early after tumor initiation, unless CXCR2 signaling is blocked; with CXCR2 blockade, there is lower myeloid-derived suppressor cell infiltration into the TME, which restores the efficacy o…”
Background
Enhancing the efficacy of vaccinia-based oncolytic virotherapy by inhibiting CXCR2-mediated MDSC trafficking
Tan, Z., Chiu, M. S., Yue, M., Kwok, H., Tse, M. H., Yang, W., Chen, B., Yang, D., Zhou, D., Song, Y., et al. (2023) · Journal of Leukocyte Biology · doi:10.1093/jleuko/qiad150 · Cited by 4
The CXCR2 chemokine receptor: A new target for gastric cancer therapy
Kang, W., Wang, C., Wang, M., Liu, M., Hu, W., Liang, X., & Zhang, Y. (2024) · Cytokine · doi:10.1016/j.cyto.2024.156675 · Cited by 4
Targeting PMN‐MDSCs via CD300ld receptor for cancer immunotherapy
Li, Y., Wang, C., Lu, Z., & Luo, M. (2024) · Clinical and Translational Medicine · doi:10.1002/ctm2.1534 · Cited by 4
“14 The inhibition of FATP2 abrogated the suppressive functions of PMN-MDSCs and sensitised anti-CTLA4 antibody treatment.”
Background
Role of myeloid cells in the tumor microenvironment
Balakrishnan, A., Vig, M., & Dubey, S. (2022) · Journal of Cancer Metastasis and Treatment · doi:10.20517/2394-4722.2022.33 · Cited by 4
IMMUNE MODULATION OF CANCER: MECHANISMS AND RESISTANCE
Lisi, L., Cari, L., Sorrentino, R., Mini, E., Fimognari, C., & Nocentini, G. (2021) · doi:10.36118/pharmadvances.2021.07 · Cited by 4
Comparative evaluation of immunomodulatory cytokines for oncolytic therapy based on a high-efficient platform for oHSV1 reconstruction
Gao, Y., Zou, Y., Wu, C., Tao, J., Nie, Z., Yan, J., Wang, P., & Huang, X. (2025) · Virology Journal · doi:10.1186/s12985-025-02758-y · Cited by 3
“…via JAK/STAT1 signaling [7], addressing antigen presentation deficiencies in TNBC. (2) GM-CSF, the cytokine payload in FDA-approved T-VEC for melanoma [8], promotes DC recruitment and maturation, but in breast cancer models, it has also been implicated in MDSC expansion and tumor progression [9].”
Loss of TRPV4 reduces pancreatic cancer growth and metastasis
Romac, J. M.-J., Swain, S. M., Mullappilly, N., Bindhani, B., & Liddle, R. A. (2025) · JCI Insight · doi:10.1172/jci.insight.196280 · Cited by 7
“Consistent with this observation, we found decreased hepatic neutrophil and myeloid cell/macrophage infiltration in TRPV4 KO mice as indicated by differential expression of the genes: S100a8/a9 (79), Cd177 (52) , Mmp8 (80) , Mpo (50) , Elane (49), and Cxcr2 (60, 81, 82).”
CXC Chemokine‐Driven Vascular Reprogramming: Modulating Tumor Vasculature to Boost Therapeutic Response
Chen, H., Huang, Y., Wu, Yi, Z., Li, Y., Yang, Z., Zhang, F., & Li, C. (2026) · Advanced Science · doi:10.1002/advs.202523331 · Cited by 3
“Targeting CXCR2 or CXCR4 with selective antagonists [ 139 ], enhancing the CXCL9/10/11-CXCR3-B pathway, or suppressing CXCL8 signaling have been reported to alleviate immune exclusion and improve vascular perfusion, with the potential to prolong normalization-like windows and enhance synergy…”
Clinically oriented immune heterogeneity in prostate cancer: emerging targets and strategies
Zhan, M., Zhao, B., Wu, J., Li, K., Chen, Y., Chen, H., Zhao, L., & Zhu, J. (2026) · Frontiers in Immunology · doi:10.3389/fimmu.2026.1753718 · Cited by 3
“These blood-and tissue-based readouts also support pharmacodynamic endpoints for CXCR1/2 blockade or IL-8-axis targeting, including rational combinations with ICIs (47, 48).”
Tumor microenvironment conversion through intelligent nanomedicine: a paradigm shift in overcoming chemoresistance
Hasannia, M., Abounoori, M., Mahmoudian, F., Shirzad, M., Rahdar, A., Duguna, S., & Pandey, S. (2026) · Frontiers in Oncology · doi:10.3389/fonc.2026.1812990 · Cited by 6
Multi-omics differences in the bone marrow between essential thrombocythemia and prefibrotic primary myelofibrosis
Zhang, A., Sun, T., Yu, D., Fu, R., Liu, X. F., Feng, X., Liu, W., Ju, M., Dai, X., Dong, H., et al. (2024) · Clinical and Experimental Medicine · doi:10.1007/s10238-024-01350-y · Cited by 3
Neutrophils: A Double-Edged Sword for Cancer Immunotherapy
Zhang, H., Qin, Y., Wei, H., & Yu, C. (2025) · ACS Nano Medicine · doi:10.1021/acsnanomed.5c00003 · Cited by 3
Self-citation
Immunotherapy, Immunobiomarkers and Gene Analysis Role in the Improvement of Lung Cancer Treatment
Wael, M., Wael, M., Hosam, M., Youssef, A., Ellackany, R., & Alzahabi, A. (2022) · Radiotherapy and Clinical Oncology · doi:10.31487/j.rco.2022.01.01 · Cited by 2
Resistance of MMTV-NeuT/ATTAC mice to anti-PD-1 immune checkpoint therapy is associated with macrophage infiltration and Wnt pathway expression
Yuan, H., Jin, L., Xiang, H., Bhattacharya, A., Brandish, P. E., Baltus, G. A., Tong, A., Zhou, C., & Glazer, R. I. (2022) · Oncotarget · doi:10.18632/oncotarget.28330 · Cited by 3
mRNA vaccines in gastric cancer: How close are we?
Portillo‐Miño, J. D., Bettin-Gonzalez, D., & Coral, F. A. M. (2024) · Vacunas (English Edition) · doi:10.1016/j.vacune.2024.02.012 · Cited by 3
Neutrophils in the tumor microenvironment: role in tumor progression and potential targeted therapeutic strategy
Shi, H., Yu, S., Li, W., Li, X., Wu, X., Qu, X., Ma, Y., Zheng, C., & Che, X. (2024) · Journal of Cancer Metastasis and Treatment · doi:10.20517/2394-4722.2023.177 · Cited by 3
Biology of Myeloid-Derived Suppressor Cells
Alicea-Torres, K. M., & Gabrilovich, D. I. (2017) · Springer eBooks · doi:10.1007/978-3-319-62431-0_10 · Cited by 3
Combining anaerobic bacterial oncolysis with vaccination that blocks interleukin-10 signaling may achieve better outcomes for late stage cancer management
Ni, G., Wang, T., Yang, L., Wang, Y., Liu, X., & Wei, M. Q. (2015) · Human Vaccines & Immunotherapeutics · doi:10.1080/21645515.2015.1089008 · Cited by 3
Two hits are better than one
Alderton, G. K. (2014) · Nature reviews. Cancer · doi:10.1038/nrc3777 · Cited by 3
Mechanisms of resistance to immune checkpoint inhibitors
Liu, X., & Guan, Q. (2020) · World Chinese Journal of Digestology · doi:10.11569/wcjd.v28.i17.857 · Cited by 3
Myeloid-derived suppressor cell-dependent inhibition of B cell responses in non-small cell lung cancer
Li, R., & Dubinett, S. M. (2019) · Translational Lung Cancer Research · doi:10.21037/tlcr.2019.04.10 · Cited by 3
“CXCR2 blockade not only impairs tumor angiogenesis but also reduces MDSC infiltration, resulting in an enhanced anti-tumor immune response (12-14).”
Background
A Spatiotemporal Model of CXCL10 as a Master Regulator of Immune Evasion and Metastasis in Osteosarcoma
Gyau, B. B., & Man, T.-K. C. (2025) · International Journal of Molecular Sciences · doi:10.3390/ijms27010319 · Cited by 3
“For example, in pancreatic adenocarcinoma, NF-κ B-driven expression of CXCL5 fosters tumor progression via recruitment of CXCR2 + myeloid-derived suppressor cells (MDSC) and tumor-associated neutrophils [43,44].”
Selenoprotein P deficiency drives hepatocellular carcinoma progression via induction of neutrophil senescence and immunosuppressive microenvironment
Jiao, J., Song, L., Xu, S., Xue, Y., Liao, Y., Xu, K., Wen, Q., Xiang, K., Chen, R., Dong, X., et al. (2026) · Gut · doi:10.1136/gutjnl-2025-336422 · Cited by 2
“71 72 Additionally, inhibiting CD300ld on the surface of neutrophils has been shown to improve the antitumour efficacy of anti- PD-1 treatment.”
Heat Shock Protein 90: From Molecular Chaperone Function to Therapeutic Targeting in Malignancies
Zhang, B., Zou, X., Zhou, J., Sun, Q., & Chen, D. (2026) · Advanced Science · doi:10.1002/advs.75895 · Cited by 2
CAR T Cell Therapy in Solid Tumors: Lessons From Early‐Phase Clinical Trials and Biological Barriers to Efficacy
Liu, K., Pham, V. T., Fu, S., Sun, L., & Huang, G. (2026) · Hematological Oncology · doi:10.1002/hon.70209 · Cited by 2
“For example, enforced expression of CXCR1 or CXCR2 enables CAR T cells to exploit IL‐8‐rich tumor microenvironments, resulting in enhanced trafficking, persistence, and antitumor efficacy in aggressive solid tumor settings [58].”
Local immunotherapy of cancer and metastasis
Kwon, S., & Yeo, Y. (2021) · Elsevier eBooks · doi:10.1016/b978-0-323-85781-9.00018-x · Cited by 2
Loss of Cxcr2 in Myeloid Cells Promotes Tumour Progression and T Cell Infiltration in Invasive Bladder Cancer
Ismail, N. F., Foth, M., Yousef, A. R. E., Cui, N., Leach, J. D. G., Jamieson, T. J., Karim, S. A., Salmond, J. M., Morton, J. P., & Iwata, T. (2022) · Bladder Cancer · doi:10.3233/blc-211645 · Cited by 2
“20 The pro-tumour role of CXCR2 was reported previously in colon cancer [44], breast cancer [45], rhabdomyosarcoma [27], and pancreatic ductal adenocarcinoma [28, 46].”
Meta-analysis of preclinical measures of efficacy in immune checkpoint blockade therapies and comparison to clinical efficacy estimates
Tenorio-Pedraza, J. M., Lippert, J., Burghaus, R., & Scheerans, C. (2023) · Translational Medicine Communications · doi:10.1186/s41231-023-00151-x · Cited by 2
“These included the cell line [13], sex [27] treatment start day [28, 29], and site of tumor injection [30].”
Background
Mathematical modeling indicates that regulatory inhibition of CD8+ T cell cytotoxicity can limit efficacy of IL-15 immunotherapy in cases of high pre-treatment SIV viral load
Cody, J. W., Ellis-Connell, A. L., O’Connor, S. L., & Pienaar, E. (2023) · PLoS Computational Biology · doi:10.1371/journal.pcbi.1011425 · Cited by 2
“Inflammation also recruits immunosuppressive cells, such as myeloid-derived suppressor cells (MDSCs) [79], which, in turn, attenuate the effectiveness checkpoint blockade therapy [80,81].”
Background
Role of the CXCL8–CXCR1/2 Axis in Cancer and Inflammatory Diseases
Mir, M. A., Bashir, M., & Ishfaq, I. (2023) · Springer eBooks · doi:10.1007/978-981-99-4657-0_11 · Cited by 2
mRNA vaccines in gastric cancer: How close are we?
Portillo‐Miño, J. D., Bettin-Gonzalez, D., & Coral, F. A. M. (2023) · Vacunas · doi:10.1016/j.vacun.2023.10.006 · Cited by 2
A novel risk score system based on immune subtypes for identifying optimal mRNA vaccination population in hepatocellular carcinoma
Zhuang, H., Tang, C., Han, L., Zhang, Z., Chen, X., Wang, W., Wang, Q., Tan, W., Yang, L., Xie, Z., et al. (2024) · Cellular Oncology · doi:10.1007/s13402-024-00921-1 · Cited by 2
“Previous studies also demonstrated that MDSCs exhibit immunosuppressive activities in TME, facilitating immune escape and non-response to ICB of tumor cells [64–67].”
Paraneoplastic leukocytosis induces NETosis and thrombosis in bladder cancer PDX model
Kuo, Y. (2024) · American Journal of Cancer Research · doi:10.62347/ihio5742 · Cited by 2
Flow cytometry-based monitoring of myeloid-derived suppressor cells in the peripheral blood of patients with solid tumors
Donaubauer, A.-J., Scheer, I., Fietkau, R., Gaipl, U. S., & Frey, B. (2024) · Methods in cell biology · doi:10.1016/bs.mcb.2024.10.009 · Cited by 2
Myeloid-derived suppressor cells modulation in the context of tumor microenvironment for gastric cancer
Portillo‐Miño, J. D., Calderón, J. J., Ruíz‐García, E., & Monge, C. (2025) · Clinical & Translational Oncology · doi:10.1007/s12094-025-03960-8 · Cited by 3
The Role of CXCR2 in Pancreatic Cancer Development and Progression
Purohit, A. (2015) · DigitalCommons@UNMC · Cited by 2
Knowing the myeloid-derived suppressor cells: Another enemy of sarcomas patients
García-Domínguez, D. J., Sánchez‐Margalet, V., de la Cruz‐Merino, L., & Hontecillas‐Prieto, L. (2023) · International review of cytology · doi:10.1016/bs.ircmb.2022.11.003 · Cited by 2
Dicer Suppresses Hepatocellular Carcinoma via Interleukin-8 Pathway
Han, X., Wu, J., Sha, Z., Lai, R., Shi, J., Mi, L., Yin, F., & Guo, Z. (2023) · Clinical Medicine Insights Oncology · doi:10.1177/11795549231161212 · Cited by 2
A heparan-sulfate-bearing syndecan-1 glycoform is a distinct surface marker for intra-tumoral myeloid-derived suppressor cells
Welte, T., Mai, J., Zhang, Z., Tian, S., Zhang, G., Xu, Y., Zhang, L., Chen, S.-S., Wang, T., & Shen, H. (2021) · iScience · doi:10.1016/j.isci.2021.103349 · Cited by 2
“Some genes have been associated with synergistically dampening immune response with PD-L1/PD-1 checkpoint axis (Trem2 [Molgora et al., 2020], Mertk and Gas6 [Holtzhausen et al., 2019; Lee-Sherick et al., 2018], CD38 [Chen et al., 2018], C1q [Roumenina et al., 2019a, 2019b]); regulatory T cell recruitment/induction (CC…”
Background
Prognostic stratification based on HIF-1α signaling for evaluating hypoxia status and immune landscape in hepatocellular carcinoma
Zhuang, H., Zhang, Z.-D., Chen, B., Tang, C.-W., Chen, X.-M., Tan, W.-L., Yang, L., Xie, Z.-Q., Ma, X.-W., Wang, Q.-B., et al. (2023) · Journal of Big Data · doi:10.1186/s40537-023-00752-1 · Cited by 1
“Moreover, previous study by Martin et al. also showed that hypoxia signaling and glycolysis-related pathways are upregulated in HCCs insensitive to TACE, and targeting PKM2, an HIF-1α-related gene, could improve the response rate to TACE [73].”
BackgroundInfluential
A Melanoma-Specific Gene Network Analysis Identifies MZB1 as a Potential Tumor Promoter
Chhabra, G., Su, S., Shirley, C. A., Thornton, J., Rizvi, H. A., Robarge, R. K., Krien, J. M., Ndiaye, M. A., & Ahmad, N. (2025) · Journal of Investigative Dermatology · doi:10.1016/j.jid.2025.07.009 · Cited by 1
Tumor–Immune Interactions in Pediatric Oral Rhabdomyosarcoma: A Narrative Review on Immuno-Oncology and Emerging Therapies
Meligy, O. E., Elemam, N. M., Hassan, W. A., & Talaat, I. M. (2025) · Children · doi:10.3390/children12091249 · Cited by 1
KRAS Withdrawal in Cholangiocarcinoma Leads to Immune Infiltration and Tumor Regression
Qiao, Y., Yee, M. F., Parikh, C. N., Ma, B., Cao, Y., Shih, Y., Wu, J. Q., Ruscetti, M. A., Liang, S., & Xue, W. (2025) · Advanced Science · doi:10.1002/advs.202511312 · Cited by 1
Breaking barriers in prostate cancer: the mRNA vaccine breakthrough and what comes next
Rajabi, R., Vafaei, S., Afrashteh, F., Ghods, R., & Madjd, Z. (2026) · npj Vaccines · doi:10.1038/s41541-025-01358-9 · Cited by 2
“…vulnerabilities such as defects in DNA Damage Repair (DDR) Pathways (e.g., in BRCA1/2) with Poly (ADP-ribose) polymerases (PARPs) inhibitors, and investigating strategies against aberrant WNT/ β -catenin signaling, are critical for developing more effective and personalized treatments 21,22 .”
A Folate Receptor β-Targeted TLR7 Agonist Significantly Augments Checkpoint Inhibitor Potencies by Reprogramming Tumor-Associated Macrophages and Myeloid-Derived Suppressor Cells
Napoleon, J. V., Alfar, R. A., Zhang, F., Raine, E. A., Wolt, T. A., & Low, P. S. (2026) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.5c03277 · Cited by 1
Targeting m 6 A Reader YTHDF1 Enhances Antitumor Immunity and Potentiates Anti‐PD‐L1 Efficacy in Intrahepatic Cholangiocarcinoma
Luo, L., Liu, Z., Song, Z., Zhang, D., Liang, C., Fang, F., Lei, K., Wang, L., Chen, W., Shen, S., et al. (2026) · Advanced Science · doi:10.1002/advs.202520403 · Cited by 1
Oncolytic viruses in cancer therapy development: the evolution of cell culture models in preclinical research
Bhalani, S., Parmar, P., Modasiya, I. J., Padhi, A., & Agarwal, A. (2026) · VirusDisease · doi:10.1007/s13337-026-00964-y · Cited by 1
“Blocking this pathway not only reduces suppressive myeloid infiltration but also restores CTL-driven tumor clearance, demonstrating that effective therapy requires simultaneous suppression of anti-viral-induced immuno-suppression [28 ].”
Myeloid-Derived Suppressor Cells in Cancer: Metabolic Reprogramming, Immune Crosstalk, and Therapeutic Targeting
Sabatini, A., Assenza, M. R., Bilotta, M. T., Vacca, P., & Tumino, N. (2026) · Cancers · doi:10.3390/cancers18132150 · Cited by 1
“Indeed, CXCR2 inhibitors have shown promise in preclinical models by improving T-cell infiltration and enhancing checkpoint blockade therapy, as well as targeting inflammatory tumor-derived cytokines (such as GM-CSF, G-CSF, IL-6) [100].”
Risk of Neurological Adverse Events Between PD-L1 and PD-1 Inhibitors in South Korean Patients with Lung Cancer: A Target Trial Emulation Framework
Kim, S. H., Lee, S., Lee, S., Chang, S.-Y., Jeon, H., & Lee, H. (2026) · Clinical Drug Investigation · doi:10.1007/s40261-026-01584-6 · Cited by 1
“…PD-1 inhibitors, along with atezolizumab and durvalumab, which are PD-L1 inhibitors, are representative ICIs used for the treatment of LC. PD-1 inhibitors and PD-L1 inhibitors disrupt PD-1/PD-L1 interaction and restore T-cell function, allowing T cells to recognize and destroy cancer cells [9–12].”
Two hits are better than one
Alderton, G. K. (2014) · Nature reviews. Immunology · doi:10.1038/nri3710 · Cited by 1
Immunological and Genetic Biomarkers of Sarcomas
D’Ambrosio, L., Sangiolo, D., Merlini, A., Grignani, G., & Aglietta, M. (2018) · Elsevier eBooks · doi:10.1016/b978-0-12-811785-9.00042-9 · Cited by 1
Hurdles in Cancer Immunotherapy
Sadeghi, F., Moghaddam, A. S., & Soleymanjahi, S. (2020) · Springer eBooks · doi:10.1007/978-3-030-50287-4_31 · Cited by 1
Intrinsic and acquired cancer immunotherapy resistance
Saleh, R., Nair, V. S., Toor, S. M., & Elkord, E. (2021) · Elsevier eBooks · doi:10.1016/b978-0-12-823397-9.00014-4 · Cited by 2
Mediating role of circulating inflammatory proteins in the effect of immune cells on esophageal cancer risk: A Mendelian randomization study
Guo, J., Si, G., Song, X., & Si, F. (2024) · Medicine · doi:10.1097/md.0000000000040374 · Cited by 1
“[66] 67-69] Mechanistically, active arginase I expressed by MDSCs inhibits CD8 T cells from secreting interferon-γ and IL-2, thereby promoting tumor growth and progression.”
Background
Enhancing the Efficacy of Checkpoint Blockade Through Combination Therapies
Juneja, V. R., LaFleur, M. W., Manguso, R. T., & Sharpe, A. H. (2016) · Springer eBooks · doi:10.1007/978-3-319-29827-6_1 · Cited by 2
Role and Therapeutic Implications of MDSCs in Sarcomas
Lala, B., Kalbasi, A. K., & Singh, A. S. (2018) · Springer eBooks · doi:10.1007/978-3-319-93530-0_1 · Cited by 1
Improving responses to immunotherapy in head and neck squamous cell carcinoma
Ye, W., Schmitt, N. C., Ferris, R. L., & Allen, C. T. (2020) · Elsevier eBooks · doi:10.1016/b978-0-12-817868-3.00006-8 · Cited by 1
Targeted delivery and reprogramming of myeloid-derived suppressor cells (MDSCs) in cancer
Katoh, H. (2021) · Elsevier eBooks · doi:10.1016/b978-0-323-85781-9.00015-4 · Cited by 1
Tackling Immune Targets for Breast Cancer Beyond PD-1PD-L1 Axis
Tabana, Y., Okoye, I., Siraki, A. G., Elahi, S., & Barakat, K. (2021) · Vide Leaf, Hyderabad eBooks · doi:10.37247/pacr.1.2021.42 · Cited by 1
Assessment of soluble immune mediators as potential biomarkers during immune checkpoint inhibitor therapy
Matsuo, N., Azuma, K., & Sasada, T. (2019) · Oncotarget · doi:10.18632/oncotarget.26749 · Cited by 1
Microbial activation converts neutrophils into anti-tumor effectorsPreprint
Yam, A. O. W., Bailey, J., Lin, F., Jakovija, A., Counoupas, C., Triccas, J. A., Gunzer, M., Bald, T., Grey, S. T., & Chtanova, T. (2020) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2020.08.21.259051 · Cited by 1
“Tumorinfiltrating neutrophils can also aid metastasis (9-11) and impair the effectiveness of antitumor immune therapies (12-15).”
Background
mRNA challenge predicts brain cancer immunogenicity and response to checkpoint inhibitorsPreprint
Castillo, P., Ogando‐Rivas, E., Geffrard, H., Pepe, A., Liu, R., Nguyen, D., Pedro, D. I., Zhang, D., DeVries, A., Qdaisat, S., et al. (2023) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2023.03.18.532056 · Cited by 1
Myeloid-Derived Suppressor Cells in Cancer
Jaya, F. N. M., & Gabrilovich, D. I. (2024) · Elsevier eBooks · doi:10.1016/b978-0-128-24465-4.00087-9 · Cited by 1
Multifaceted Aspects of Dysfunctional Myelopoiesis in Cancer and Therapeutic Perspectives with Focus on HCC
Arleo, A., Montagner, A., Giovannini, C., Suzzi, F., Piscaglia, F., & Gramantieri, L. (2024) · Biomolecules · doi:10.3390/biom14121496 · Cited by 1
“Indeed, blocking the MDSCs seems to strengthen PD-1 checkpoint inhibition, with a pivotal role played by CXCR2 receptors in this process [179].”
The novel roles of stromal fibroblasts in metronomic chemotherapy: Focusing on cancer stemness and immunity
Liao, W., Chan, T., & Tsai, K. K. (2017) · Journal of Cancer Research and Practice · doi:10.1016/j.jcrpr.2017.08.001
Monoclonal Antibodies Targeting the Immune System
Minard‐Colin, V. (2017) · Springer eBooks · doi:10.1007/978-3-319-43486-5_7
REOVIRUS-DRIVEN MYELOID CELLS IN ONCOLYTIC VIRUS THERAPY AND INFECTION
Clements, D. R. (2018) · DalSpace (Dalhousie University)
Immune Checkpoint Inhibitors in Gastrointestinal Malignancies
Fountzilas, C. K., Lee, S. S., Iyer, R. V., & Boland, P. M. (2018) · Elsevier eBooks · doi:10.1016/b978-0-323-54948-6.00004-4
Modulation of Myeloid-Derived Suppressor Cells Amplification by Tumor Microenvironment
张, 瑞. (2021) · Advances in Clinical Medicine · doi:10.12677/acm.2021.1111741
The Impact of Myeloid-Mediated Co-Stimulation and Immunosuppression on the Anti-Tumor Efficacy of Adoptive T cell Therapy
Innamarato, P. (2020) · Digital Commons - University of South Florida (University of South Florida)
Pulmonary Delivery of Engineered Exosomes to Suppress Postoperative Melanoma Lung Metastasis through Preventing Premetastatic Niche FormationPreprint
Han, X., Bi, L., Wu, Y., Yan, J., Wu, X., Zheng, R., Sun, Y., Wang, Y., & Zhang, H. (2021) · Research Square · doi:10.21203/rs.3.rs-1133189/v1
Self-citation
Immune Checkpoints are Important Therapeutic Targets in Cancer Immunotherapy
Ratna, A., Mukherjee, S., & Das, S. K. (2021) · Cancer Science & Research · doi:10.33425/2639-8478.1079
“The efficacy of PD-1 blockade was shown to be improved when tumor trafficking of MDSC was inhibited after anti-CXCR2 mAb therapy [133].”
Background
Faculty Opinions recommendation of Combination Approaches with Immune-Checkpoint Blockade in Cancer Therapy.
Eisenlohr, L. C., & Cosma, G. L. (2018) · Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature · doi:10.3410/f.726981821.793545053
Disección mecanística del fracaso loco-regional en cáncer de mama
de Córdoba, B. R. (2022) · Deposito Adademico Digital Universidad De Navarra (University of Navarra) · doi:10.15581/10171/63818
Shaping of the Immune Landscape by Chemokine Receptors that Impacts the Clinical Outcome in Triple-Negative Breast Cancer
Dulal, D., Boring, A. R., Terrero, D., Tiwari, A. K., & Raman, D. (2022) · Interdisciplinary cancer research · doi:10.1007/16833_2022_20
Checkpoint Blockade in Hematologic Malignancies
Charalambous, A., & Schwarzbich, M. (2022) · Springer eBooks · doi:10.1007/978-3-030-80962-1_178-1
Data from Myeloid-Derived Suppressor Cells Are a Major Source of Wnt5A in the Melanoma Microenvironment and Depend on Wnt5A for Full Suppressive Activity
Douglass, S. M., Fane, M. E., Sanseviero, E., Ecker, B. L., Kugel, C. H., Behera, R., Kumar, V., Tcyganov, E. N., Yin, X., Liu, Q., et al. (2023) · doi:10.1158/0008-5472.c.6512631.v1
Data from Hepatitis B–Induced IL8 Promotes Hepatocellular Carcinoma Venous Metastasis and Intrahepatic Treg Accumulation
Zhang, C., Gao, Y., Du, C., Markowitz, G. J., Fu, J. W., Zhang, Z., Liu, C., Qin, W., Wang, H., Wang, F., et al. (2023) · doi:10.1158/0008-5472.c.6513549.v1
Data from Claudin-12 Deficiency Inhibits Tumor Growth by Impairing Transendothelial Migration of Myeloid-Derived Suppressor Cells
Cao, H., Ni, C., Han, L., Wang, R., Blasig, R., Haseloff, R. F., Qin, Y., Lan, J., Lou, X., Ma, P., et al. (2023) · doi:10.1158/0008-5472.c.6514082.v1
Data from mDKN-01, a Novel Anti-DKK1 mAb, Enhances Innate Immune Responses in the Tumor Microenvironment
Haas, M., Kagey, M. H., Heath, H., Schuerpf, F., Rottman, J. B., & Newman, W. (2023) · doi:10.1158/1541-7786.c.6545285.v1
Data from Driver Mutations Dictate the Immunologic Landscape and Response to Checkpoint Immunotherapy of Glioblastoma
Yeo, A. T., Shah, R., Aliazis, K., Pal, R., Xu, T., Zhang, P., Rawal, S., Rose, C. M., Varn, F. S., Appleman, V. A., et al. (2023) · doi:10.1158/2326-6066.c.6597334
Trial protocol 1 from Efficacy of Nivolumab in Pediatric Cancers with High Mutation Burden and Mismatch Repair Deficiency
Das, A., Tabori, U. Y., Nahum, L. C. S., Collins, N. B., Deyell, R. J., Dvir, R., Faure‐Conter, C., Hassall, T., Minturn, J. E., Edwards, M., et al. (2023) · doi:10.1158/1078-0432.23284759.v1
Trial protocol 1 from Efficacy of Nivolumab in Pediatric Cancers with High Mutation Burden and Mismatch Repair Deficiency
Das, A., Tabori, U. Y., Nahum, L. C. S., Collins, N. B., Deyell, R. J., Dvir, R., Faure‐Conter, C., Hassall, T., Minturn, J. E., Edwards, M., et al. (2023) · doi:10.1158/1078-0432.23284759

Authors: Highfill, S. L., Cui, Y., Giles, A. J., Smith, J. P., Zhang, H., Morse, E., Kaplan, R. N., & Mackall, C. L.
Affiliations: National Institutes of Health (US)
Corresponding author: Mackall, Crystal L.
ORCID: Highfill, Steven L.
Cui, Yongzhi
Giles, Amber J.
Zhang, Hua
Kaplan, Rosandra N.
Mackall, Crystal L.
Venue: Science Translational Medicine
Publisher: American Association for the Advancement of Science (AAAS)
Published: 2014-05-21
Volume: 6
Issue: 237
Pages: 237ra67-237ra67
ISSN: 1946-6234 (ISSN-L)
1946-6242
DOI: 10.1126/scitranslmed.3007974
PMC: PMC6980372
OpenAlex: W2171524684
Cited by: 767
References: 50
Citations by year: 2026: 55 · 2025: 62 · 2024: 57 · 2023: 83 · 2022: 73 · 2021: 100 · 2020: 91 · 2019: 60 · 2018: 52 · 2017: 52 · 2016: 38 · 2015: 31 · 2014: 12
FWCI: 20.24
Type: journal article
Language: en
Open access: green
www.ncbi.nlm.nih.gov
Locations: Science Translational Medicine (publishedVersion)
PubMed (publishedVersion)
PubMed Central (acceptedVersion)
Funders: National Institutes of Health
National Cancer Institute (Z01BC011072, Z01BC010566, Z01SC010289)
Topics: Life Sciences › Immunology and Microbiology › Immunology › Immune cells in cancer
Health Sciences › Medicine › Oncology › Cancer Immunotherapy and Biomarkers
Health Sciences › Medicine › Oncology › Chemokine receptors and signaling
Keywords: CXCR2, myeloid-derived suppressor cells, tumor immune evasion, anti-PD-1 therapy, rhabdomyosarcoma, pediatric sarcoma, interleukin-8, PD-L1, tumor immunosuppression
MeSH terms: Adolescent, Adult, Animals, Antibodies, Monoclonal, Antigens, Ly, Antineoplastic Combined Chemotherapy Protocols, Chemotaxis, Child, Child, Preschool, Female, Humans, Male, Mice, Inbred C57BL, Prognosis, Rhabdomyosarcoma, Time Factors, Neoplastic Stem Cells, Case-Control Studies, Cytokines, Interleukin-8, Mice, Knockout, Tumor Escape, Receptors, Interleukin-8B, CD11b Antigen, Cell Line, Tumor, Tumor Burden, Mice, Chemokine CXCL1, Young Adult, Tumor Microenvironment, B7-H1 Antigen

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Disruption of CXCR2-Mediated MDSC Tumor Trafficking Enhances Anti-PD1 Efficacy

Abstract

Overview

Integrity signals

Verification

Claims the paper makes

Claims other papers make about this one

Self-check

Citations

Cites

Cited by

Related

Metadata

Record

About these checks